Biochemical Relationship Between Beta-Hydroxybutyrate and Acetone in DKA
Beta-hydroxybutyrate (β-OHB) is the predominant ketone body produced during DKA, while acetone forms through spontaneous decarboxylation of the intermediate ketone acetoacetate—making acetone a byproduct rather than a primary metabolic acid. 1
The Metabolic Pathway
During insulin deficiency in DKA, the liver converts free fatty acids into three ketone bodies in this sequence:
- β-OHB (the primary and most abundant ketone—an actual acid)
- Acetoacetate (intermediate ketone—also an acid)
- Acetone (formed by spontaneous breakdown of acetoacetate—neutral, not an acid)
Acetone is produced through non-enzymatic decarboxylation of acetoacetate and is eliminated primarily through respiration, which explains the characteristic fruity breath odor in DKA 1.
Critical Clinical Implications for Monitoring
The relationship between these ketones creates a monitoring paradox that can mislead clinicians during DKA treatment. 2
Why β-OHB is Superior for Monitoring:
- β-OHB is the strongest and most prevalent acid in DKA 2
- Traditional nitroprusside methods (urine dipsticks and some serum tests) only detect acetoacetate and acetone—they completely miss β-OHB 2
- During DKA treatment, β-OHB is converted back to acetoacetate, which paradoxically makes urine ketones appear to worsen even as the patient improves 2
The Monitoring Pitfall:
As DKA resolves with insulin therapy:
- Blood β-OHB decreases (actual improvement)
- Acetoacetate temporarily increases (conversion product)
- Urine ketones may increase or remain positive (lag effect)
- This can falsely suggest worsening ketosis 2, 1
Therefore, urine ketone measurements should NOT be used to assess response to DKA therapy 2. Blood β-OHB measurement is the preferred method 2.
Quantitative Relationships
The correlation between these markers in DKA patients shows:
- Skin acetone concentrations correlate with blood β-OHB (r=0.669, p<0.01) 3
- In DKA cases, median β-OHB reaches 1085 mg/L with median acetone of 330 mg/L 4
- The absence of acetone essentially precludes pathologically significant β-OHB elevation (>250 mg/L), making acetone useful as an initial screening marker 5
- However, 24% of cases show elevated β-OHB with normal urine ketones, particularly in patients with impaired kidney function 6
Practical Algorithm for DKA Monitoring
- Initial assessment: Measure blood β-OHB directly (not urine ketones)
- During treatment: Follow blood β-OHB levels every 2-4 hours
- Ignore rising urine ketones during treatment—this reflects conversion, not worsening
- Resolution criteria: Blood β-OHB normalization, not urine ketone clearance
Blood β-OHB >250 mg/L is pathologically significant for ketoacidosis 5, while normal range is <50 mg/L 5.
The key takeaway: acetone is a metabolic byproduct of acetoacetate breakdown, not a primary driver of acidosis, and its measurement can be misleading during DKA treatment when β-OHB (the actual culprit acid) is being cleared.